Join
Live feed
·
INSIDERFilingvia Quantisnow
Regulus Therapeutics Inc. logo

President & Head of R & D Klassen Preston sold $39,721 worth of shares (31,445 units at $1.26), decreasing direct ownership by 47% to 36,055 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RGLS· Regulus Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RGLS (Regulus Therapeutics Inc.) and more on Quantisnow.